Colon Cancer Stage III Clinical Trial
Official title:
Phase III Study of Neoadjuvant FOLFOXIRI Chemotherapy Versus Immediate Surgery for High-risk Resectable Stage II and III Colon Cancers
BACKGROUND: In patients with high risk stage II and stage III colon cancer (CC), curative surgery followed by adjuvant chemotherapy with FOLFOX or CAPOX regimens has become a standard treatment. However, 20 to 30 % of these patients will develop distant metastasis, which ultimately result in death. Perioperative chemotherapy is a promising strategy with potential benefits that could be more effective at eradicating micrometastases. Moreover, shrinking tumor before surgery not only facilitate removal of all the tumor by the surgeon but also reduce tumor cell spreading during the procedure. With recent advances in radiology, preoperative computed tomography allows a good prediction of tumor stage (wall penetration and nodal involvement) prior to surgery. The investigators conducted the present randomized study to explore whether perioperative chemotherapy with FOLFOXIRI regimen compared with postoperative chemotherapy could improve disease-free survival in patients with radiologically staged, High-risk, but resectable Stage II or III colon cancer. OBJECTIVE: The primary objective of this study is to evaluate the efficacy of perioperative chemotherapy with FOLFOXIRI regimen compared to postoperative chemotherapy in patients with High-risk Resectable Stage II and III colon cancer. Secondary objectives are efficacy in terms of R0 resection rate, overall survival (OS), relapse-free survival (RFS), down-staging of primary tumors, and tolerability of perioperative therapy and postoperative complications.
This trial is a a two-arm, multicenter, open labelled, prospective, randomized phase III studies. Eligible patients with High-risk Resectable Stage II and III (T4 or T3 with extramural depth≧5 mm) colon cancer patients will be randomly assigned, in a 2:1 ratio, to receive either perioperative or postoperative chemotherapy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Completed |
NCT00309530 -
Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C
|
Phase 3 | |
Completed |
NCT04342676 -
Lymph Node Ratio and Kras Mutation in R Colon Cancer
|
Phase 3 | |
Enrolling by invitation |
NCT05179889 -
Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT05433402 -
Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06108310 -
ArTificial inTelligence-based RAdiogenomics in Colon Tumors
|
||
Withdrawn |
NCT05310565 -
The Effects of Chiropractic in Adults With Colon Cancer
|
N/A | |
Not yet recruiting |
NCT04488159 -
Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer
|
Phase 3 |